Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAILOR-CSU
2024-513155-32-00Phase 2Authorised
- Sponsor
- Philipps-Universität Marburg
- Start
- Mar 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of risankizumab in chronic idiopathic urticaria (CIU), sponsored by Philipps-Universität Marburg. Primary endpoint: Change in UAS7 from baseline to week 20. Planned start Mar 2026; status: authorised.
02
Drugs
risankizumab
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on 2024-513155-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513155-32-00.